CO2021000158A2 - Pharmaceutical composition containing a peptide - Google Patents

Pharmaceutical composition containing a peptide

Info

Publication number
CO2021000158A2
CO2021000158A2 CONC2021/0000158A CO2021000158A CO2021000158A2 CO 2021000158 A2 CO2021000158 A2 CO 2021000158A2 CO 2021000158 A CO2021000158 A CO 2021000158A CO 2021000158 A2 CO2021000158 A2 CO 2021000158A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
peptide
composition containing
composition
irritable
Prior art date
Application number
CONC2021/0000158A
Other languages
Spanish (es)
Inventor
Christopher Rupp
Ronny Schulze
Den Akker Rob Van
Kuldeep Bhokare
Jörn Lüders
George Shlieout
Jörg Hagedorn
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of CO2021000158A2 publication Critical patent/CO2021000158A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica estable para administración oral que comprende linaclotida o sales farmacéuticamente aceptables de la misma y un vehículo. Asimismo, se proporcionan métodos para preparar y usar la composición. En particular, la composición se puede usar en el tratamiento de trastornos gastrointestinales, tales como estreñimiento crónico y síndrome del intestino irritable. irritable.The present invention relates to a stable pharmaceutical composition for oral administration comprising linaclotide or pharmaceutically acceptable salts thereof and a carrier. Also provided are methods for preparing and using the composition. In particular, the composition can be used in the treatment of gastrointestinal disorders, such as chronic constipation and irritable bowel syndrome. irritable.

CONC2021/0000158A 2018-07-09 2021-01-12 Pharmaceutical composition containing a peptide CO2021000158A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811025533 2018-07-09
PCT/IB2019/000716 WO2020012243A2 (en) 2018-07-09 2019-07-08 Pharmaceutical composition containing a peptide

Publications (1)

Publication Number Publication Date
CO2021000158A2 true CO2021000158A2 (en) 2021-01-18

Family

ID=68165587

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000158A CO2021000158A2 (en) 2018-07-09 2021-01-12 Pharmaceutical composition containing a peptide

Country Status (6)

Country Link
AR (1) AR115724A1 (en)
BR (1) BR112021000201A2 (en)
CL (1) CL2021000022A1 (en)
CO (1) CO2021000158A2 (en)
MX (1) MX2021000312A (en)
WO (1) WO2020012243A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033427A1 (en) 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
MX2020005326A (en) 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration.
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016521249A (en) 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド Linaclotide composition
WO2016024291A1 (en) 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
EP3233059A1 (en) * 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide

Also Published As

Publication number Publication date
AR115724A1 (en) 2021-02-17
CL2021000022A1 (en) 2021-07-19
WO2020012243A3 (en) 2020-03-05
MX2021000312A (en) 2021-06-08
BR112021000201A2 (en) 2021-08-10
WO2020012243A2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CO2019000945A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
GT201600142A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING AZD9291
EA201892657A1 (en) SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION
DOP2018000297A (en) DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
CO2019000943A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
BR112015020389A8 (en) carbazole compounds useful as bromodomain inhibitors, their use as well as pharmaceutical composition and product comprising them
CO2019000944A2 (en) Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof
CO2019000941A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
EA201792487A1 (en) COMPOSITIONS OF HYDROXYPROPYL-BET-CYCLODEXTRINS AND METHODS
AR101674A1 (en) USE OF A TRICYCLIC COMPOUND CONTAINING NITROGEN
CO2016003340A2 (en) Pharmaceutical formulations, processes for preparation and methods of use
PE20130782A1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF PARACETAMOL AND THE PROCESS FOR THE PREPARATION OF THE SAME
CO2021000158A2 (en) Pharmaceutical composition containing a peptide
ECSP15033649A (en) A COMBINED MEDICINAL PRODUCT INCLUDING PHENYLEPHRINE AND PARACETAMOL
CO2022000211A2 (en) Pharmaceutical compositions resistant to dose discharge comprising comeunad
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
CL2018003707A1 (en) Dosing regimens of vortioxetine for the rapid onset of the antidepressant effect.
ECSP18001655A (en) Composition of multiple peptides
DOP2019000233A (en) DROPROPIZIN IN COMBINATION WITH AMBROXOL IN THE PHARMACEUTICAL FORM OF SYRUP AND TABLET
EA201991288A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN
CO2019008347A2 (en) Quick release composition of cinitapride and simethicone and process to prepare it
GT201500333A (en) PHARMACEUTICAL SYNERGISTIC COMPOSITION OF TWO ANALGESICS WITH DIFFERENT FAMACOCINETIC PROFILE
TR201719926A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PHARMACEUTICALLY ACCEPTABLE LITHIUM SALTS AND VITAMIN C
CU20130165A7 (en) MODIFIED RELEASE OF 4-METHYL-3 - [[- 4- (3- PIRIDINIL) -2-PYRIMIDINYL] AMINO] -N-5- (4- METHYL-1H-IMIDAZOL-1- IL) -3- (TRIFLUOROMETIL) FENIL] SOLUBILIZED BENZAMIDE USING ORGANIC ACIDS